Use of Social Media for Pharmacovigilance Activities: Key Findings and Recommendations from the Vigi4Med Project

Bissan Audeh (), Florelle Bellet, Marie-Noëlle Beyens, Agnès Lillo-Le Louët and Cédric Bousquet
Additional contact information
Bissan Audeh: LIMICS, Sorbonne Université, Inserm
Florelle Bellet: Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord
Marie-Noëlle Beyens: Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord
Agnès Lillo-Le Louët: Centre Régional de Pharmacovigilance HEGP, AP-HP
Cédric Bousquet: LIMICS, Sorbonne Université, Inserm

Drug Safety, 2020, vol. 43, issue 9, No 2, 835-851

Abstract: Abstract The large-scale use of social media by the population has gained the attention of stakeholders and researchers in various fields. In the domain of pharmacovigilance, this new resource was initially considered as an opportunity to overcome underreporting and monitor the safety of drugs in real time in close connection with patients. Research is still required to overcome technical challenges related to data extraction, annotation, and filtering, and there is not yet a clear consensus concerning the systematic exploration and use of social media in pharmacovigilance. Although the literature has mainly considered signal detection, the potential value of social media to support other pharmacovigilance activities should also be explored. The objective of this paper is to present the main findings and subsequent recommendations from the French research project Vigi4Med, which evaluated the use of social media, mainly web forums, for pharmacovigilance activities. This project included an analysis of the existing literature, which contributed to the recommendations presented herein. The recommendations are categorized into three categories: ethical (related to privacy, confidentiality, and follow-up), qualitative (related to the quality of the information), and quantitative (related to statistical analysis). We argue that the progress in information technology and the societal need to consider patients’ experiences should motivate future research on social media surveillance for the reinforcement of classical pharmacovigilance.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00951-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:9:d:10.1007_s40264-020-00951-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00951-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().